Takeda Pharmaceutical Co. Ltd. · TSE:4502
Takeda Pharmaceutical — Investor Presentation (September 2018)
17 slides from Takeda Pharmaceutical's investor presentation, September 2018
Slide 1: Takeda Vaccines: Innovation for Global Impact
TAKEDA VACCINES INNOVATION FOR GLOBAL IMPACT RAJEEV VENKAYYA, MD President, Global Vaccine Business Unit
Slide 2: Our Mission
OUR MISSION Develop and deliver innovative vaccines that tackle the toughest problems in public health and improve the lives of people around the world 2
Slide 3: We have built a global vaccine business upon a strong foundation in Japan
WE HAVE BUILT A GLOBAL VACCINE BUSINESS UPON A STRONG FOUNDATION IN JAPAN Global pivotal Phase 3 PARTNERSHIPS clinical trial of dengue Polio vaccine ACQUISITIONS vaccine candidate initiated: candidate Japan vaccine business Global vaccine business Dengue vaccine 20,100 participants in 8 candidate Bi
Slide 4: The vaccine market is an attractive place for investment
THE VACCINE MARKET IS AN ATTRACTIVE PLACE FOR INVESTMENT Vaccine sales growth projected at 7.1% between Durability in sales with limited impact 2017 and 2024, reaching $44.6 billions in 20241 of patent expiry Blockbuster potential in newly launched vaccines Threat of emerging and existing infectious
Slide 5: Our Strategy
OUR STRATEGY Develop vaccines with global BUILD A GLOBAL TACKLE Target the greatest opportunity relevance and business potential PIPELINE UNMET NEED in infectious diseases LEVERAGE PARTNERSHIPS Partner to de-risk and drive vaccine development 5
Slide 6: Our Pipeline
OUR PIPELINE Discovery/preclinical Phase 1 Phase 2 Phase 3 Japan Marketed Vaccines EGG-BASED DENGUE VACCINE SEASONAL FLU (TAK-003) H5N1 FLU DENKA & KM BIOLOGICS (BLB-750) NOROVIRUS VACCINE MEASLES VARICELLA^ (TAK-214) RUBELLA+ BIKEN BARDA JAPANESE SABIN INACTIVATED MUMPS ENCEPHALITIS ZIKA VACCINE PO
Slide 7: Dengue threatens half of the world's population
DENGUE THREATENS HALF OF THE WORLD’S POPULATION In 2015, >85 M Endemic in more than Causes an estimated Causes more than 120 countries1 390 M infections1 20K deaths each year2 US, Canada, and Japan travelers to endemic countries3 Without safe and effective dengue vaccine >3.9 BILLION people around t
Slide 8: A safe and effective dengue vaccine should protect against all four strains
A SAFE AND EFFECTIVE DENGUE VACCINE SHOULD BE DESIGNED TO PROTECT AGAINST ALL FOUR STRAINS OF THE VIRUS • Dengue is a mosquito-borne disease that can be caused by each of the four strains of the dengue virus (DENV) 1-4 • In people previously exposed to dengue, a subsequent infection with a different
Slide 9: TAK-003 is modeled on the complete dengue virus and activates multiple arms of the immune system
TAK-003 IS MODELED ON THE COMPLETE DENGUE VIRUS AND ACTIVATES MULTIPLE ARMS OF THE IMMUNE SYSTEM • Live attenuated dengue vaccine based on the complete DENV-2 genome • Vaccine virus stimulates robust immune response without causing illness • Components of immune response that are activated include:
Slide 10: TAK-003 triggers both antibody and cell-mediated immune responses
TAK-003 TRIGGERS BOTH ANTIBODY AND CELL-MEDIATED IMMUNE RESPONSES 100% % of Subjects with a Dengue- Percentage of participants specific T-cell Response 80% Participants responding to: 60% 3 or 4 serotypes 40% All 4 serotypes 20% 0% 28 91 180 540 Days Antibody-mediated immune response in dengue naïve
Slide 11: TAK-003 triggers NS1 antibodies that prevent vascular leakage in the laboratory
TAK-003 TRIGGERS NS1 ANTIBODIES THAT PREVENT VASCULAR LEAKAGE IN THE LABORATORY1 Endothelial Permeability • Severe dengue is characterized by vascular leakage (Relative TEER) in the lungs and abdomen • This vascular leakage is thought to be mediated by the dengue virus non-structural protein 1 (NS1)
Slide 12: TAK-003 was generally safe and reduced dengue incidence in children in Phase 2
TAK-003 WAS GENERALLY SAFE AND REDUCED THE INCIDENCE OF DENGUE IN CHILDREN IN A RECENT PHASE 2 STUDY INCIDENCE OF SYMPTOMATIC DENGUE WAS SIGNIFICANTLY LOWER IN VACCINE RECIPIENTS OVER 18 MONTHS1 STUDY FEATURES • 1,800 participants received either TAK-003 (1 dose; 2 Dengue Incidence doses at 0, 3 mon
Slide 13: Our Phase 3 pivotal trial is designed to answer the most important questions
OUR PHASE 3 PIVOTAL TRIAL IS DESIGNED TO ANSWER THE MOST IMPORTANT QUESTIONS ABOUT SAFETY AND EFFICACY OF OUR DENGUE VACCINE CANDIDATE STUDY DESIGN PRIMARY ENDPOINT SECONDARY ANALYSIS: ENDPOINT ANALYSIS: • 20,100 participants, aged 4 – 16 years old OVERALL VACCINE VACCINE EFFICACY IN - Age range ens
Slide 14: Takeda has the most advanced norovirus vaccine candidate (TAK-214)
TAKEDA HAS THE MOST ADVANCED NOROVIRUS VACCINE CANDIDATE (TAK-214) AND RECENTLY COMPLETED PHASE 2B STUDY CHALLENGE • Leading cause of acute gastroenteritis – 600M infections per year • No vaccine available OUR PATH • Most advanced vaccine in development • Completed Phase 2b study • Phase 3 preparati
Slide 15: Takeda has partnered with the U.S. Government to develop the first Zika vaccine
TAKEDA HAS PARTNERED WITH THE U.S. GOVERNMENT TO DEVELOP THE FIRST ZIKA VACCINE (TAK-426) CHALLENGE • Devastating impact on newborns • Potential for recurrent outbreaks • No vaccine available OUR PATH • Largest Zika investment by U.S. government • Proven platform • Fast track designation OUR GOAL •
Slide 16: Conclusion
CONCLUSION 1 STRONG FOUNDATION AND TOP TALENT • Over 70 years of 2 BEST-IN-CLASS AND FIRST-IN-CLASS POTENTIAL • Dengue vaccine 3 A PARTNER OF CHOICE FOR VACCINES • U.S. Government vaccine manufacturing (TAK-003) in Phase 3 • Japan Government experience • Norovirus vaccine • Bill & Melinda Gates • To
Slide 17: Bill Gates quote on vaccines as an investment
“If you want to save and improve lives around the world, vaccines are a fantastic investment.” - Bill Gates
Takeda Pharmaceutical — Investor Presentation (September 2018) on 6ix